Skip to main content

Table 4 Clinical and disease characteristics of CML patients at base line

From: Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival

Disease characteristics

CML Patients (n = 150)

Imatinib 400-mg OD dose group (n = 59)

Imatinib 600-mg OD dose group (n = 91)

Splenomegaly, n (%)

 No

57 (38)

27 (47)

30 (53)

 Yes

93 (62)

32 (34)

61 (66)

Hepatomegaly, n (%)

 No

113 (75)

44 (39)

69 (61)

 Yes

37 (25)

15 (40.5)

22(59.5)